白雲山(00874.HK)子企獲委托生產複方感冒靈膠囊
白雲山(00874.HK)(600332.SH)公布,其全資子公司中一藥業收到廣東省藥品監督管理局核准簽發的《藥品生產許可證》,同意中一藥業接受公司子公司奇星藥業委托生產複方感冒靈膠囊,受託生產車間為製造一部、製造二部、製造三部、南村提取車間,受託生產線為:硬膠囊劑生產線、中藥前處理及提取(口服制劑)生產線,受託時間與委托批准時間一致。
公司指出,上述事項有利於公司優化資源配置,繼續保持穩定的生產能力,滿足市場需求,是次獲得《藥品生產許可證》,對公司當期業績無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.